Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
May 15 2017 - 3:42PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SEC File Number
000-51474
|
|
CUSIP Number
74365B109
|
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One):
☐
Form 10-K
☐
Form 20-F
☐
Form 11-K
☒
Form 10-Q
☐
Form 10-D
☐
Form N-SAR
☐
Form N-CSR
For period ended:
March 31,
2017
|
☐
|
Transition Report on Form 10-K
|
|
☐
|
Transition Report on Form 20-F
|
|
☐
|
Transition Report on Form 11-K
|
|
☐
|
Transition Report on Form 10-Q
|
|
☐
|
Transition Report on Form N-SAR
|
For the transition period ended:
__________________________
Read Instruction (on back page) Before
Preparing Form. Please Print or Type.
Nothing in this form shall be construed
to imply that the Commission has verified any information contained herein.
|
If the notification relates to a portion of the filing checked
above, identify the item(s) to which the notification relates:
PART I—REGISTRANT INFORMATION
Protea Biosciences Group,
Inc.
Full Name of Registrant
1311 Pineview Drive, Suite 501
Address of Principal Executive Office
(Street and Number)
Morgantown, WV 26505
City, State and Zip Code
PART II—RULE 12b-25(b) and (c)
If the subject report could not be filed
without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.
(Check box if appropriate)
☒
|
(a)
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
☒
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
|
☐
|
(c)
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III—NARRATIVE
State below in reasonable detail the reason
why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed
time period.
(Attach extra sheets if needed)
The Registrant is unable to file its
Interim Report on Form 10-Q for the fiscal quarter ended March 31, 2017 (the “Report”) by the prescribed date of May
15, 2017, without unreasonable effort or expense, because the Registrant and its independent auditor need additional time to complete
certain disclosures and analyses to be included in the Report. In accordance with Rule 12b-25 promulgated under the
Securities Exchange Act of 1934, as amended, the Registrant intends to file its Report on or prior to the fifteenth calendar day
following the prescribed due date.
PART IV—OTHER INFORMATION
|
(1)
|
Name and telephone number of person to contact with regard to this notification.
|
|
Stephen Turner
|
|
(304)
|
|
292-2226
|
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) or the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
|
☒
Yes
☐
No
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
☒
Yes
☐
No
If so, attach an explanation of the anticipated
change, both narratively and quantitatively, and, if appropriate, state the reason why a reasonable estimate of the results cannot
be made.
It is likely that there will be significant
changes in the Company's revenues and operating expenses for the three months ended March 31, 2017 as compared to the three months
ended March 31, 2016. However, a reasonable estimate of such changes cannot be made at this time because the financial statements
are still being compiled.
Protea Biosciences Group, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed
on its behalf by the undersigned heretofore duly authorized.
Date: May 15, 2017
|
By
|
/s/ Stephen Turner
|
|
Name: Stephen Turner
|
|
Title: Chief Executive Officer
|